pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Ozempic · news · pharmadog
← back to Ozempic
News mentioning Ozempic
216
stories
Oct 1, 26
#EASD26: Regeneron's antibody helps patients regain muscle after stopping GLP-1 therapy
endpoints
Oct 1, 26
Sanofi pays Dupixent partner Regeneron $1B upfront for 4 early-stage assets to ignite R&D
fiercebiotech
Sep 30, 26
Superior weight loss, blood sugar control propel Lilly’s amylin-GIP/GLP-1 combo into Phase 3
biospace
Sep 30, 26
#EASD26: Lilly's amylin-Zepbound combo posts best-ever weight loss in patients with obesity and diabetes
endpoints
Sep 30, 26
Lilly builds commercial case for GLP-1 products over Novo with indirect analyses
biospace
Sep 30, 26
Lilly raises diabetes weight-loss bar with amylin-Zepbound combo
fiercebiotech
Sep 29, 26
FDA Investigation Leads to Charges Against Two Indian Nationals Involved in Transnational Counterfeit Drug Distribution Scheme
fda press
Sep 29, 26
Novo to pay Hengrui up to $2.6B for a once-weekly obesity pill
biopharma dive
Sep 29, 26
Novo adds long-term obesity differentiation in up to $2.6B Hengrui deal
biospace
Sep 28, 26
Roche drops muscle-sparing obesity antibody after flunked interim analysis
fiercebiotech
Sep 28, 26
STAT+: Once described as obesity medicines for ‘patients,’ GLP-1s are increasingly lifestyle drugs for ‘customers’
stat
Sep 25, 26
This week in charts: Novo’s rise and fall and AI biotechs’ big haul
biopharma dive
Sep 24, 26
FDA slams GLP-1 compounder over risk of contaminating drugs ‘with filth’
biospace
Sep 23, 26
STAT+: Pharmalittle: We’re reading about a closing loophole for importing meds, European competitiveness, and more
stat
Sep 23, 26
Novo’s turnaround plan, weight loss wins, Ultragenyx’s Sanfilippo approval, IPO blitz
biospace
Sep 22, 26
Viking shares surge on updated obesity drug data
biopharma dive
Sep 22, 26
Novo targets 10-fold jump in oral Wegovy manufacturing capacity by 2030
biospace
Sep 22, 26
Novo’s workforce reduction climbs to 13,000 to fuel R&D work
biospace
Sep 22, 26
Siemens Healthineers and Novo team up on fatty liver disease awareness, testing
fiercebiotech
Sep 22, 26
Roche’s GLP-1/GIP drug hits in phase 2 diabetes trial, fueling best-in-disease hopes
fiercebiotech
Sep 21, 26
Novo talks up drug launches in effort to win back investors
biopharma dive
Sep 21, 26
Novo’s plan to hit $23B in revenue by 2035 leaves investors wanting
biospace
Sep 21, 26
Novo buys three early-stage obesity assets from Kallyope as investor pressure mounts
biospace
Sep 21, 26
Novo struggles to appease restive investors with consumer plans, blockbuster ambitions
fiercebiotech
Sep 21, 26
Are healthcare systems really ready for GLP-1s?
biopharma dive
Sep 18, 26
Artelo’s ex-AstraZeneca cannabinoid agonist holds its own against GLP-1 drug semaglutide in obese mice
fiercebiotech
Sep 18, 26
Refreshed Novo corrals 3 new early-stage obesity drugs from Kallyope
fiercebiotech
Sep 17, 26
Novo partners with Orbis, deepening investment in oral peptide drugs
biopharma dive
Sep 17, 26
Novo notches up to $1.4B pact with Orbis to develop oral macrocycle cardiometabolic drugs
biospace
Sep 16, 26
'Still a bull': Novo's CEO on honoring heritage and planning for the future amid corporate rebrand
fiercebiotech
← prev
page 3 of 8
next →